Fate Therapeutics, Inc. (FATE)

Fate Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Cash & Equivalents	136.5	57.05	76.56	148.81	182.57	100.04
Short-Term Investments	262.22	273.31	374.89	482.33	315.57	121.61
Cash & Cash Equivalents	398.72	330.35	451.45	631.14	498.14	221.65
Cash Growth	-5.99%	-26.82%	-28.47%	26.70%	124.74%	10.15%
Receivables	0.86	1.83	38.48	8.68	5.52	0
Other Current Assets	-5.2	-0.64	12.14	-6.4	-9.34	5.44
Total Current Assets	394.38	331.54	502.07	633.41	494.32	227.09
Property, Plant & Equipment	152.74	158.51	176.09	162.25	99.39	34.17
Long-Term Investments	7.6	0.98	4.94	100.66	0	39.44
Other Long-Term Assets	15.19	15.19	22.46	25.13	28.74	1.57
Total Long-Term Assets	175.52	174.68	203.49	288.04	128.13	75.19
Total Assets	569.89	506.22	705.56	921.46	622.46	302.27
Accounts Payable	6.77	4.72	8.27	8.61	6.28	5.82
Deferred Revenue	0.16	0.69	42.23	48.61	67.17	6.56
Current Debt	6.4	6.18	5.63	5.58	3.36	1.69
Other Current Liabilities	32.04	27.51	57.93	18.49	8.76	13.73
Total Current Liabilities	45.37	39.09	114.05	81.28	85.56	27.81
Long-Term Debt	95.67	97.36	103.71	109.24	93.94	25.24
Other Long-Term Liabilities	2.74	1.35	3.86	52.09	58.51	4.48
Total Long-Term Liabilities	98.41	98.71	107.57	161.33	152.45	29.71
Total Liabilities	143.78	137.8	221.62	242.62	238.01	57.52
Total Debt	102.07	103.54	109.34	114.82	97.3	26.93
Debt Growth	-5.15%	-5.31%	-4.77%	18.01%	261.34%	80.91%
Retained Earnings	-1,259.74	-1,211.73	-1,050.8	-769.08	-556.93	-383.55
Comprehensive Income	-0.19	0.02	-1.85	-0.76	0.07	0.02
Shareholders' Equity	426.12	368.42	483.94	678.84	384.45	244.76
Net Cash / Debt	296.65	226.82	342.12	516.32	400.85	194.73
Net Cash / Debt Growth	-6.27%	-33.70%	-33.74%	28.81%	105.85%	4.50%
Net Cash Per Share	2.93	2.30	3.53	5.45	4.87	2.86
Working Capital	349.01	292.45	388.02	552.13	408.76	199.28
Book Value Per Share	4.21	3.74	5.00	7.17	4.67	3.59

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).